← Leaderboards
Edwin Melencio Posadas
Cedars-Sinai Medical Center
$4,564,053
Attributed
$7,810,294
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,810,294 · 5
By mechanism
R01$4,138,241 · 2
U01$2,354,242 · 1
P01$1,317,811 · 2
Top collaborators
- Hsian-Rong Tseng10 shared
- Neil A Bhowmick2 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Neil A Bhowmick$9,206,432
- Ekihiro Seki$13,011,862
- Margareta Pisarska$10,063,746
Others in their field
Top investigators on “Blood”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$381,545,820
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$292,209,610
- Chanza Baytop · Westat, Inc.$271,217,917
- Mary M Horowitz · Medical College Of Wisconsin$240,114,780
Research focus
BloodInsightSamplingNeoplasm Circulating CellsTumorBlood SpecimenMedical CenterVariantNanovelcroMalignant NeoplasmsCessation Of LifeMalignant Neoplasm Of ProstateMonitorCancer PatientDisease ProgressionLiverResourcesProgramsTranslatingBiologicalNatural HistoryGenotypeCastration Resistant Prostate CancerMicrofluidics
Grant awards (17)
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients$575,242
R01 · FY2025 · CA
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients$553,550
R01 · FY2024 · CA
Core B: Liver Metastasis Resource Core (LMRC)$215,306
P01 · FY2024 · CA · contact PI
Core B: Liver Metastasis Resource Core (LMRC)$337,190
P01 · FY2023 · CA · contact PI
Core B: Liver Metastasis Resource Core (LMRC)$246,376
P01 · FY2022 · CA · contact PI
A blood test to identify prostate cancer patients at risk for visceral metastasis$601,752
R01 · FY2021 · CA · contact PI
Core B: Liver Metastasis Resource Core (LMRC)$251,389
P01 · FY2021 · CA · contact PI
A blood test to identify prostate cancer patients at risk for visceral metastasis$601,750
R01 · FY2020 · CA · contact PI
Core B: Liver Metastasis Resource Core (LMRC)$267,550
P01 · FY2020 · CA · contact PI
A blood test to identify prostate cancer patients at risk for visceral metastasis$583,697
R01 · FY2019 · CA · contact PI
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling$455,920
U01 · FY2019 · CA
A blood test to identify prostate cancer patients at risk for visceral metastasis$601,750
R01 · FY2018 · CA · contact PI
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling$470,021
U01 · FY2018 · CA
A blood test to identify prostate cancer patients at risk for visceral metastasis$620,500
R01 · FY2017 · CA · contact PI
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling$470,021
U01 · FY2017 · CA
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling$471,503
U01 · FY2016 · CA
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling$486,777
U01 · FY2015 · CA